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Background: Chemokines play multiple roles in the development and progression in a variety of tumors.
Chemokine (C-X-C motif) ligand 7 (CXCL7) has been found associated with pro-inflammatory responses, but its role
in cancer growth remains unclear. Our previous study showed that R phase tumor infiltrating lymphocytes (TILs)
produced large amounts of interleukin (IL)-6 which antagonized transforming growth factor (TGF)-β derived from
CTVT to diminish the immune-suppressive microenvironment. Now we intend to determine the expression pattern
of CXCL7 and the role of IL-6/TGF-β in CXCL7 induction during spontaneous progressive (P) and regressive (R)
phases in canine transmissible venereal tumor (CTVT).
Results: We have demonstrated that CXCL7 expressed at high level in P phase and down-regulated in R phase by
western blot and real-time PCR. This suggested that CXCL7 expression was negatively correlated with the tumor
growth. Co-culturing TILs with CTVT cells was found to reduce CXCL7 expression, while adding IL-6 blocking
antibody reversed it. Moreover, in P phase CTVT, while IL-1β and TGF-β had no obvious effect on CXCL7 expression,
IL-6 was found significantly to reduce CXCL7 expression in a dose-dependent manner. The mRNA expression results
of CXCL7 receptor, CXCR2, further confirmed the effects of IL-6 concentration on the CXCL7 expression.
Conclusion: CXCL7 overexpression might be associated with the progressive growth of CTVT. The results shown
here also suggest the role of CXCL7 in cancer development and the potential as the anti-cancer therapeutic target.
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Canine transmissible venereal tumor (CTVT) is a
unique tumor that is transmitted by viable tumor cells
[1] through injured mucosa and skin. CTVT cells have a
stabilized genome with almost identical dog leukocyte
antigen class II loci, which may have originated in
wolves [1]. The tumor cells effectively evade the host’s
histocompatibility (MHC) barrier for long periods, and
transplanted cells grow liberally in the progression (P)
phase for a few months or over 1 year [2,3]. This immu-
noevasion was found partly because of the high concen-
tration of tumor-secreted Transforming growth factor-β* Correspondence: redman@ntu.edu.tw; cslin100@ntu.edu.tw
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reproduction in any medium, provided the or(TGF-β), which inhibits tumoral MHC antigen expres-
sion and the activity of natural killer cells [4]. However,
the immune systems of most hosts eventually reject the
transplanted cells in the regression (R) phase [5]. One
mechanism for this rejection is related to interleukin
(IL)-6 produced by tumor-infiltrating lymphocytes (TIL)
that counteract the activities of TGF-β [4]. CTVT is one
of the few tumors that allow us to study detailed dy-
namic changes in host–cancer interactions during spon-
taneous regression of a tumor.
Chemokines are classified as a group of 8–10 kDa pro-
teins with structural similarity and chemotactic activity
[6]. Chemokines are generated by leukocytes and several
types of stromal cells and are chemoattractants for a wide
range of leukocytes. Chemokines play an important role in
lymphocyte migration, recirculation, modulation of im-
mune response, and leukocyte recruitment to the inflam-
mation sites. There are in the main two subfamilies ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CXCL7 expression is concordant with the CTVT
progression phase. (A) Levels of mRNA expression of CXCL7 from
CTVT tumor masses (n = 4) measured by real-time RT-PCR. The
amounts of mRNA are expressed relative to the amount of β-actin
mRNA in each sample and are shown as the mean ± S.D. (**, P < 0.01).
(B) Western blot analysis of CXCL7 protein expressed in CTVT. CXCL7
proteins were recognized by polyclonal rabbit antibody against canine
CXCL7 in the lysates of CTVT tumor masses. Actin was used as the
internal control.
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of the first two cysteines, which can be either adjacent (C-
C) or separated by one other amino acid (C-X-C). CXC
chemokines act on neutrophils, and maintain the amino-
terminal sequence Glu-Leu-Arg (ELR) motif, which is ne-
cessary for receptor recognition and signaling [7]. One of
the ELR+CXC chemokines, Chemokine (C-X-C motif) li-
gand 7 (CXCL7), has been shown to activate neutrophils
for chemotaxis over a wide range of stimulus concentra-
tions [8], for the degranulation of lysosomal enzymes [9]
and to increase adhesion molecules on these cells [10].
Activated CXCL7 induces the recruitment of neutrophils
to the site of inflammation or injury. Increased CXCL7
levels were detected in epithelial cells isolated from clinical
patients with active ulcerative colitis, which suggests that
CXCL7 contributes to the sustained neutrophil presence
in these patients. However, unlike other ELR+CXC chemo-
kines [11-13], the relationship between CXCL7 and cancer
has not been well investigated.
In the tumor microenvironment, chemokines and their
receptors play pivotal roles in regulating angiogenesis,
cell migration and tumor growth and help to clarify the
progression of the cancer [14]. Some particular chemo-
kine–receptor pairs are included in tumor metastasis by
their chemoattractants function in cell migration. In
addition, chemokines make the tumor microenviron-
ment more suitable for tumor growth by induction of
leucocytes migration and activation of inflammatory
responses [14]. Recently accumulated evidence shows
that chemokine receptor signaling also contributes to
tumor survival and proliferation, mainly due to their mi-
gratory promotion activities [15]. Many studies have
shown that CXC chemokines are co-expressed in a va-
riety of tumors [11-13] and account for the higher
aggressiveness of tumors [11].
Our previous study showed that canine dendritic cells
(DC) derived from peripheral blood express CXCL7
mRNA and secrete CXCL7 protein in response to chronic
inflammation inducing cytokines, such as IL-1β, IL-6,
TGF-β and Tumor necrosis factor (TNF)-α, but not to
acute inflammation-associated cytokines, such as Inter-
feron (IFN)-γ and lipopolysaccharides (LPS) [16]. These
findings suggest that DC produce CXCL7 in a chronic in-
flammation site under an immune tolerance situation. We
also demonstrated that only an immunologically-favorable
microenvironment can fully support the maturation of DC
[17], and CTVT have the ability to induce an immune es-
cape microenvironment [4,18,19]. Therefore, we hypothe-
sized that the tumor microenvironment of CTVT may
involve CXCL7 expression and allow CXCL7 to achieve
chronic inflammation and tumor progression.
The relationship between CXCL7 and CTVT is inves-
tigated in this study. It was found that CXCL7 overex-
pression was associated with the progression phase ofCTVT, while during the regression phase, the tumor
cells express a very low level of CXCL7. In addition, we
also revealed that TIL-derived IL-6 down-regulated
CXCL7 expression in CTVT. These results suggest a
novel role of CXCL7 in cancer progression.Results
Association between CXCL7 overexpression and tumor
growth pattern
The mRNA levels of CXCL7 in the tumor masses from
the P and R phase were determined by real-time RT-PCR.
As shown in Figure 1A, the CXCL7 mRNA expression
was significantly higher in the P phase than in the R phase
(P < 0.01). Western blotting revealed that in comparison
with the R phase, the CXCL7 protein was significantly up-
regulated in the CTVT P phase (Figure 1B). The specific
bands were normalized with the internal control β-actin.
These data show that CXCL7 increased concordantly with
CTVT progressive growth both in terms of the mRNA
and protein expression levels.
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CTVT cells
To find the factor that regulated the expression of
CXCL7, we cocultured P-phase CTVT cells with R-
phase TIL using a transwell system. The P-phase CTVT
cells were separated from R-phase TIL using the 0.4 μm
pore size of the transwell system. After 12 h coculture,
the CXCL7 expression was significantly decreased
(Figure 2). The inhibitory effect could be achieved even
in 1:10 ratio of TIL: CTVT cells. This result suggested
that TIL might secrete some soluble substances to in-
hibit the production of CXCL7.
The expression of CXCL7 was regulated by IL-6 in CTVT
cells
As the IL-6 produced by R-phase TIL counteracts the
activities of TGF-β to induce CTVT regression [5], we
further confirmed that the expression of CXCL7 wasFigure 2 R-phase TIL inhibited the expression of CXCL7 in
P-phase CTVT cells. A coculture system was analyzed using a Corning
transwell system, in which TIL cells (0.1–1×106 cells/well) were seeded
in the upper chamber, with a 0.4-μm-pore filter between that and a
lower chamber containing CTVT cells (1×106 cells/well). (A) After 12 h
of incubation, the gene expression of CXCL7 in the CTVT cells was
evaluated. (B) CXCL7 protein expression was also analyzed after 24-h
incubation. Significant differences in the various stimulators are
expressed as * (P < 0.05) and ** (P < 0.01) as compared with CTVT
alone. The results represent the mean ± S.D. of three independent
experiments.regulated by IL-6. The responses of the expression of
CXCL7 and its receptor, CXCR2, to different doses of
IL-6 were studied. The expression pattern of CXCL7
(Figure 3A) coincided with that of CXCR2 (Figure 3B).
CXCL7 and CXCR2 were down-regulated with high-
dose IL-6 treatment in a dose response fashion. How-
ever, when the concentration of IL-6 was low, such as 10
ng/mL, the CXCL7 production was higher than that in
tumor cells without any IL-6 treatment (Figure 3).
Regulation of CXCL7 expression in CTVT cells
To further investigate the expression of CXCL7 in CTVT,
we aimed to examine endogenous signals that up- or
down-regulate CXCL7 expression. IL-1β is a common
cytokine that stimulates CXCL7 expression [20]. In our
previous study, we found that TGF-β was elevated in theFigure 3 CXCL7 and CXCR2 expression in P-phase CTVT cells
was regulated by IL-6. Levels of mRNA expression of CXCL7 (A)
and CXCR2 (B) after freshly prepared P phase CTVT cells were
treated with 10, 30 or 90 ng/mL IL-6 for 12 h, measured by real-time
RT-PCR. The results represent the mean ± S.D. of three independent
experiments (* P < 0.05 as compared with the CTVT alone group).
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activities were regulated by IL-6 released from TIL [5].
Based on these observations, we used IL-1β and TGF-β to
verify the up-regulation of CXCL7 and used IL-6 to inves-
tigate the inhibition of CXCL7 expression in CTVT cells.
As shown in Figure 4, IL-1β and TGF-β did not increase
the CXCL7 expression in comparison with CTVT cells
alone while IL-6 significantly down-regulated the expres-
sion of CXCL7 in tumor cells. In addition, the inhibition
effect of IL-6 was not influenced by the combination of
IL-1β and TGF-β. The IL-6-mediated CXCL7 decreaseFigure 4 CXCL7 expression in CTVT under IL-1β, TGF-β and IL-6
stimulation. (A) Levels of mRNA expression of CXCL7 after freshly
prepared P-phase CTVT cells were treated with IL-1β, TGF-β and/or IL-6
(90 ng/mL) for 12 h, measured by real-time RT-PCR. The amounts of
mRNA are expressed relative to the amount of β-actin mRNA in each
sample and are shown as the mean ± S.D. (B) 1 μg/ml of anti-IL-6
antibody was adding into the TIL/CTVT cocultured transwell system.
TIL cells (0.3 × 106 cells/well) were seeded in the upper chamber and
the lower chamber containing CTVT cells (1 × 106 cells/well). After 12
h incubation, the CXCL7 gene expression in the CTVT cells was
evaluated. Significant differences in the various stimulators are
expressed as ** (P < 0.01) as compared with CTVT alone.could be further demonstrated since blocking IL-6 activity
in TILs significantly reversed this reduction (Figure 4B).
Together, these results indicated that the down-regulation
of CXCL7 in the R phase may due to the IL-6 produced
by TIL.
Discussion
The importance of CXCL7 in regulating tumorogenesis
in colon cancer has been reported [20]. Our current
observations provide further insight into the potential
importance of CXCL7 signaling in promoting tumor
growth and progression. Several studies have suggested
that high expression of ELR+CXC chemokines in vivo
and in vitro is associated with a poor prognosis [21,22].
These studies pointed out that high levels of ELR+CXC
chemokines, including CXCL7, are associated with
enhanced tumor growth [20]. High levels of CXC che-
mokines are associated with risk of recurrence after
tumor resection [12]. One report indicated that increa-
sing numbers of tumor infiltrating neutrophils in
advanced cancer are associated with reduced mortality
[23]. Neutrophils can either exclude tumor cell popula-
tions or provide for their invasive potential [24,25]. Neu-
trophil recruitment by ELR+CXC chemokines help
tumor cells to metastasize to lymph nodes [12]. Further-
more, ELR+CXC also have the ability to stimulate tumor
cell proliferation [13]. CXCL7 overexpression in P-phase
CTVT confirmed this observation.
In this study, we found that TIL-derived IL-6 played a
key role in the modulation of CXCL7 expression in
CTVT. The presence of soluble IL-6R in combination
with IL-6 affects the recruitment of leukocyte subpopu-
lations through the concurrent ability of the active com-
plex to suppress ELR+CXC chemokine expression
induced by proinflammatory cytokines (IL-1β and TNF-
α) [26]. IL-6 is a pleiotropic cytokine that is produced by
many kinds of cells. Depending on the target, IL-6 can
suppress growth, elicit growth, or influence differen-
tiation [27,28]. IL-6 can directly elevate the functions of
NK cells including proliferation, cytotoxicity, and the ex-
pression of surface activation antigen and adhesion
molecules [29]. IL-6 and its soluble receptor (sIL-6R) are
important in the regulation of leukocyte recruitment
[30]. Our data were consistent with these observations.
IL-6 could suppress the expression of CXCL7 in CTVT
cells. Furthermore, although CTVT-derived TGF-β plays
a role in damaging the host immune system during the
P phase, TIL-derived IL-6 is responsible for the recovery
of immune cells activity during the R phase [18]. Al-
though IL-6 is present in the TIL supernatants of both
the P and R phases, its concentration is significantly
higher in the R-phase TIL supernatant [5]. This may in-
dicate IL-6 inhibits CXCL7 expression is one of the
mechanism responsible for activating host immune
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tion of IL-6 produced in the P phase may act as an in-
ducer for CXCL7 expression.
Many reasons for the induction of chemokine/receptor
expression have been identified. Chemokine receptor ex-
pression is regulated both at the transcriptional level and
post-transcriptionally via RNA stability, translation and
receptor desensitization and internalization [15,31,32].
The tumor microenvironment, and mutant proteins or
changed signaling in the tumor cell itself, can also in-
fluence the chemokine receptor levels. Conditions
present within cancer, such as hypoxia or a rich cytokine
environment, can induce the transcription of chemokine
receptors [15,32]. The increased expression of CXCR2
in CTVT cells may potentially activate CXCL7 signaling
in an autocrine/paracrine pattern, the result of which
appears to enhance CTVT cell survival and growth in
the host.
In the P phase, IL-1β and TGF-β were expressed at a
high level [5]. Tumor-derived TGF-β causes serious
immune-inhibition in dogs with CTVT [4,18,19,33]. This
encourages us to further investigate the relationship
between TGF-β and CXCL7. However, neither IL-1β nor
TGF-β could induce greater CXCL7 expression in P-phase
CTVT cells (Figure 4). This may be the reason for which
freshly isolated CTVT cells alone could express very high
levels of CXCL7, so CTVT cells treated with IL-1β or
TGF-β failed to express CXCL7 at a higher level than
CTVT cells alone. Another possibility is that TGF-β could
not induce CXCL7 expression in CTVT cells.
Conclusion
In conclusion, overexpression of CXCL7 was found to
be associated with advanced tumor stage. IL-6 played a
modulation role in the expression of CXCL7 in CTVT.
Through multiple mechanisms, CXCL7 may be involved
in the migration and invasion of cancer cells and in
tumor progression. These host–cancer interactions and
the mechanisms behind them deserve further study.
Another valuable endeavor is research into the mecha-
nisms by which hosts develop efficient ways to defend
themselves against tumors that grow over months. Further
studies are needed to confirm and understand this inter-
esting observation and to determine whether CXCL7 may
serve as a therapeutic target for cancer treatment.
Methods
In vivo tumor growth
The institutional animal care and use committee of Na-
tional Taiwan University approved this study before its
start. Spontaneous CTVT on the external genitals of a
male dog was used for the original transplantation. Six
beagles aged 1–1.5 years were used for the experiments.
Each beagle was subcutaneously injected with a freshlyprepared suspension containing 7.5 × 107 viable tumor
cells at eight sites on their backs. The dimensions of the
tumors were measured with a caliper once a week, and
the volume was estimated as (π × length × width ×
thickness)/4 in cubic centimeters [5]. A tumor increasing
in volume was classified as a P-phase tumor, and one de-
creasing in volume was classified as an R-phase tumor.
MHC expression and the TIL subpopulations of tumors
in the P and R phases were analyzed to confirm the
growth phases.
Purification of CTVT cells and tumor infiltrating
lymphocytes
Every 2–3 wk post-inoculation, tumor tissue samples
were surgically excised from the experimental dogs. The
methods previously described were followed to isolate
CTVT tumor cells and TIL [4]. Briefly, 10 g of aseptic
tumor tissue was minced in 90 mL HBSS (Invitrogen).
To obtain a single cell suspension, samples were me-
chanically crushed with stainless steel mesh and filtered
once through two pieces of gauze (pore size: 190 μm).
Then, 8 mL of the cell suspension was overlaid on 4 mL
42% Percoll (GE healthcare) gradient and centrifuged at
820 ×g and 4°C for 25 min. After centrifugation, CTVT
cells deposited at the interface were harvested and
washed three times with DMEM (Invitrogen) supple-
mented with 10% FCS. TIL deposited at the bottom of
tube were collected carefully and washed three times
with RPMI 1640 (Invitrogen) supplemented with 10%
FCS. The purified CTVT cells and TIL were stained with
Hemacolor (Merck) to confirm their purities. Freshly
isolated CTVT cells and TIL (1 × 106 cells/mL) were
cultured at 37°C for future use. To prepare activated
CTVT cells, cells were incubated with different concen-
trations (10, 30 and 90 ng/mL) of IL-6 (Peprotech), 250
pg/mL of TGF-β (R&D systems), and 10 ng/mL of IL-1β
(Peprotech) for 12 h, respectively.
Extraction of RNA from CTVT
Total RNA was extracted from CTVT tumor masses or
cells separately with TRIzol (Invitrogen) according to the
manufacturer’s recommendations for cultured cells. The
amount of total RNA was determined spectrophotomet-
rically at 260 nm.
Reverse transcription of mRNA into cDNA
Using a SuperScript II reverse transcriptase kit (Invitro-
gen), 2 μg mRNA were transcribed into cDNA with a final
concentration of 5.5 mM MgCl2, 0.5 mM of each dNTP,
2.5 μM random hexamers, 0.4 U/μL RNase inhibitor, and
1.25 U/μL multiscribe reverse transcriptase, in a reaction
volume of 10 μL. The samples were incubated at 80°C for
10 min, followed by transcription at 37°C for 60 min, and
enzyme inactivation at 95° for 5 min.
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The primer sequences were designed to bind specifically
to canine CXCL7 and CXCR2 cDNA using the Primer3
software, available online (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi), and purchased from Mission
Biotech (Taipei, Taiwan). The sequences of the primer
pairs were as follows: 50- AGACCTAAGGCCACCTCCTC -30
with 50- GGAACTTCGCTGCATGTGTA -30 for canine
CXCL7 cDNA and 50- TCATCTTTGCTGTCGTGCTC -30
with 50- TGTGGAAGAAGCCCAGAATC -30 for canine
CXCR2 cDNA. A housekeeping gene, β-actin, was uti-
lized. The GenBank accession numbers of the targets as
well as the primer sequences are given in our previous
publication [33].
Real-time RT-PCR
Real-time RT-PCR was performed on an IQ5 real-time
PCR detection system (Bio-Rad) using IQ SYBR Green
PCR Supermix (Bio-Rad) according to the manufacturer’s
guidelines. PCR was conducted in 96-well optical reaction
plates as described previously [34]. The relative mRNA
amount in each sample was calculated based on the Ct in
comparison with the Ct of the housekeeping genes, and
the mRNA was ascribed a fold induction of 1. The results
are presented as 2-(Ct of target gene – Ct of housekeeping gene) in
arbitrary units, as described in a previous publication [33].
Western blot analysis
CTVT cells were lysed in 250 μL of LaemmLi sam-
ple buffer (Bio-Rad) and eluted by 5 min of boiling.
Electrophoretic separation of the cell lysates was per-
formed in 15% acrylamide gels, and bands were trans-
ferred onto polyvinylidene difluoride (PVDF) membranes
(Immobilon-P membrane, Millipore). For immuno-
blotting, the membranes were probed with anti-actin mAb
(MAB1501, Chemicon International Inc.) at a 1/2500
dilution or rabbit anti-CXCL7 polyclonal antibody (pAb)
at a 1/500 dilution. The blots were incubated with rabbit
anti-mouse or goat anti-rabbit conjugated HRP secon-
dary antibodies (Jackson ImmunoResearch Laboratories).
The signals were revealed by ECL (GE healthcare).
Statistical analysis
All results are expressed as the mean ± S.D. and were
analyzed with a two-tailed Student’s t test. Differences
were considered statistically significant at P < 0.05.
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